Latest Content

Top 3 Takeaways From ASCO GU 2025

March 25th 2025, 8:16pm

By Dr. Emre Yekedüz

Video

Dr. Emre Yekedüz discusses his top 3 key takeaways from attending the 2025 ASCO Genitourinary (GU) Cancers Symposium.

New Cancer Vaccine, EVM14, Cleared for Investigational Drug Application

March 25th 2025, 7:05pm

By Spencer Feldman

Article

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach this stage.

Navigating a Diagnosis of Diabetes and Chronic Lymphocytic Leukemia

March 25th 2025, 5:00pm

By Chester Freeman

Article

Managing diabetes and chronic lymphocytic leukemia is challenging, but with proactive care, mindfulness and diet changes, I'm working to balance both.

Olvi-Vec Shows Responses and Tolerable Safety in Small Cell Lung Cancer

March 25th 2025, 4:14pm

By Alex Biese

Article

Positive preliminary data from the phase 1b/2 trial evaluating Olvi-Vec in small cell lung cancer have been announced.

First Patient Dosed with Efti in Phase 3 Trial for Non-Small Cell Lung Cancer

March 25th 2025, 3:34pm

By Spencer Feldman

Article

The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced non-small cell lung cancer.

Raising Awareness for Colorectal Cancer, On the Rise in Younger Adults

March 25th 2025, 1:00pm

By Alex Biese

Article

During Colorectal Cancer Awareness Month, Dr. Shyam Thakkar discussed rates of this disease in young adults, the role of AI and disparities in care.

Global Submission Seeks Approval for Sugemalimab Treatment in NSCLC

March 24th 2025, 9:00pm

By Ryan Scott

Article

An application was submitted to the European Medicines Agency seeking approval for treatment with sugemalimab in stage 3 NSCLC following chemoradiotherapy.

Navigating RRMM: Helpful Resources and Advice for Patients Facing Disease Progression

March 24th 2025, 8:59pm

By Saad Usmani, MD

Video

Panelists discuss how multiple myeloma support resources range from formal organizations like the International Myeloma Foundation and Multiple Myeloma Research Foundation to online patient communities, hospital-based support groups, and specialized social media networks, with advice for newly relapsed patients emphasizing the importance of allowing emotional processing before taking action, seeking second opinions from myeloma specialists, asking detailed questions about all available options including clinical trials, connecting with patients who’ve undergone similar treatments, maintaining hope amid setbacks, and recognizing that relapses, while challenging, often open doors to novel therapeutic approaches that can effectively control the disease for extended periods.

Guidance for Caregivers: Supporting a Loved One Through Late-Line RRMM

March 24th 2025, 8:56pm

By Saad Usmani, MD

Video

Panelists discuss how caregivers supporting loved ones with late-line relapsed/refractory multiple myeloma (RRMM) should prioritize both patient and self-care by establishing sustainable support systems, maintaining open communication with the health care team, educating themselves about treatment options while acknowledging emotional boundaries, creating practical organizational systems for medication management and appointment tracking, seeking respite care when needed, connecting with caregiver support groups for shared experiences, participating in decision-making without overshadowing the patient’s voice, preparing contingency plans for complications, and finding moments of normalcy and joy amid the challenges of advanced disease management.

Effective Communication Strategies: Sharing Concerns With Your Medical Team in Late-Line RRMM

March 24th 2025, 8:54pm

By Saad Usmani, MD

Video

Panelists discuss how effective communication with medical teams in advanced multiple myeloma requires proactive strategies including preparing prioritized question lists before appointments, bringing a designated note-taking advocate to consultations, utilizing patient portals for nonurgent concerns, clearly articulating quality of life impacts rather than just symptom presence, requesting dedicated time for treatment planning discussions, recording conversations (with permission) for later review, maintaining symptom diaries with specific details, and establishing relationships with nurse navigators who can facilitate more timely responses—approaches that collectively ensure patient needs are comprehensively addressed despite the complex nature of late-line treatment decisions.

Addressing the Most Common Concerns Patients and Caregivers Have in Late-Line RRMM

March 24th 2025, 8:51pm

By Saad Usmani, MD

Video

Panelists discuss how patients and caregivers at the late-line treatment stage commonly struggle with profound concerns about diminishing treatment options, increased uncertainty about prognosis, managing complex and often cumulative side effects, financial toxicity from years of therapy, caregiver burnout, practical challenges of more frequent hospitalizations, anxiety about becoming refractory to novel agents, navigating clinical trial eligibility, maintaining hope while being realistic and balancing aggressive treatment approaches with quality of life considerations as therapeutic choices narrow.

Lifestyle Modifications That Have Been Helpful in RRMM

March 24th 2025, 8:49pm

By Saad Usmani, MD

Video

Panelists discuss how lifestyle modifications have become crucial coping strategies for managing multiple myeloma symptoms and treatment side effects, with patients reporting benefits from structured exercise regimens tailored to their energy levels, anti-inflammatory dietary approaches, mindfulness practices and meditation for pain management, consistent sleep hygiene routines, strategic activity pacing throughout the day, hydration protocols, complementary therapies like acupuncture or massage and intentional social engagement—approaches that, while not replacing medical interventions, significantly enhance quality of life and resilience throughout the treatment journey.

Aligning Treatment Goals: Key Considerations for Patients and Caregivers in Late-Line RRMM

March 24th 2025, 8:45pm

By Saad Usmani, MD

Video

Panelists discuss how quality of life priorities shift in late-line multiple myeloma treatment, with patients emphasizing the importance of maintaining independence in daily activities, preserving cognitive function, managing pain effectively, minimizing treatment-related side effects that impact social engagement, balancing treatment schedules to allow for meaningful family time and personal milestones and finding psychological peace through spirituality or support systems—ultimately revealing that while disease control remains critical, the ability to live with purpose and dignity increasingly shapes treatment decisions as patients progress through multiple therapy lines.

Balancing Efficacy and Quality of Life in Late-Line RRMM

March 24th 2025, 8:42pm

By Saad Usmani, MD

Video

Panelists discuss how balancing treatment effectiveness with quality of life in late-line multiple myeloma therapy requires a highly personalized approach, with patients and physicians collaboratively weighing factors such as potential for deeper or longer remissions against toxicity profiles, treatment logistics (inpatient vs. outpatient administration), impact on daily activities, financial toxicity, caregiver burden and individual patient goals, with many emphasizing that this calculus shifts as patients progress through treatment lines—often prioritizing aggressive approaches earlier while placing greater emphasis on maintaining functionality and meaningful life experiences in later treatment stages.

Balancing Benefits and Risks: Patients’ Experiences With Newer Therapies and Side Effects in Late-Line RRMM

March 24th 2025, 8:40pm

By Saad Usmani, MD

Video

Panelists discuss how physician-patient conversations about newer multiple myeloma therapies have evolved to include detailed discussions of potential benefits (higher response rates, novel mechanisms of action) alongside unique toxicity profiles (cytokine release syndrome with immunotherapies, neurotoxicity with CAR-T, skin/nail issues with GPRC5D-targeted agents), with patients sharing diverse experiences ranging from minimal side effects to significant complications that required hospitalization, emphasizing the importance of thorough preparation, proactive management strategies and realistic expectations when embarking on these innovative but potent treatment approaches.